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Abstract
Purpose The majority of research on psychological outcomes for cancer patients has focussed on the role of individual charac-
teristics, and disease and treatment factors. There has been very little exploration of the potential contribution of the treatment
clinic to these outcomes. This study explored whether there is variation among clinics in cancer patients’ psychological
outcomes.
Methods Cancer outpatients were recruited from 22 medical oncology and haematology clinics in Australia. Participants com-
pleted a pen and paper survey including the Hospital Anxiety and Depression Scale (HADS), as well as sociodemographic,
disease and treatment characteristics.
Results Of those eligible to participate, 4233 (82%) consented and 2811 (81% of consenters) returned the completed survey.
There was no statistically significant variation in HADS depression scores across clinics. Some difference in anxiety scores
derived from the HADS questionnaire between clinics (p = 0.03) was found with the percentage of between-clinic variation
estimated to be 1.11%. However, once all demographic, disease and treatment predictors were adjusted for there was no statistical
differences between clinics (percent of between-clinic variation = 0.53%; p = 0.1415).
Conclusions Psychological outcomes were not found to vary between clinics. Other sources of variation including patient
characteristics may over-ride between-clinic variability, if it exists.
Keywords Cancer . Oncology . Psychological . Anxiety . Depression . Quality of care
Background
There is an abundance of research indicating that people with
cancer experience high rates of depression and anxiety [1–3].
Despite recognition of the importance of addressing adverse
psychological outcomes, these conditions remain under-
detected and under-treated in many oncology and
haematology settings [4, 5]. Consequently, there is a need to
delineate the contributing factors that may have an effect on
patient psychological outcomes.
What factors may influence psychological outcomes
for people with cancer?
Non-modifiable individual characteristics such as age and
gender [2] have been associated with psychological outcomes.
Potentially modifiable individual factors such as coping strat-
egies [6] and social support [7] have also been linked to poorer
psychosocial outcomes. The association between disease and
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treatment characteristics has also been examined. Compared
to other people with cancer, those undergoing current treat-
ment [8], and people diagnosed with poor prognosis cancers
such as lung, or cancers with complex treatment regimens
such as haematological cancers tend to have poorer psycho-
logical outcomes [2, 9, 10].
It is also possible that there are differences between clinics
in patient psychosocial outcomes. Variation in patient out-
comes has been observed across a number of other areas of
health care. For example, the Dartmouth Atlas of Health Care
has documented a fivefold regional variation in rate of leg
amputations for patients with diabetes [11]. This may be due
to regional variation in the management of diabetes across
indicators such as blood glucose testing and control, blood
cholesterol testing and control, smoking cessation and foot
care to identify and treat ulcers [11]. Similarly, regional vari-
ation in unplanned readmissions following treatment for pe-
ripheral artery disease ranged from 1 in 3 to 1 in 10 [11]. After
adjustment for casemix, analyses of national claims data in the
US showed that variability in mortality following cancer re-
section was influenced by both hospital volume and surgeon
volume [4].
Several other studies have provided evidence of variation
in factors that potentially relate to psychological outcomes.
Jacobsen and colleagues reported variation in indicators of
psychological care across 11 medical outpatient clinics. The
study relied on medical records data, so it was unclear to what
extent the variation observed related to actual differences in
care patterns or to variation in the quality of documentation.
Variation in patients’ psychological outcomes was not exam-
ined. There is some evidence of variation in related outcomes
such as patient experience and pain across cancer clinics. A
Korean study involving 34 palliative care centres revealed
significant variation in pain management outcomes between
centres. Higher scores for human resource adequacy were as-
sociated with better pain outcomes suggesting that
organisational factors played a role in the observed variation
in pain outcomes across centres [12].
Despite evidence for between-clinic variations in care prac-
tices which may be expected to influence psychosocial out-
comes, there has been limited exploration of whether psycho-
social outcomes vary across clinics. Our previous study in-
volving radiation oncology clinics indicated that rates of anx-
iety varied from 24 to 34%; while depression varied from 13
to 20% [13]. These differences were not statistically signifi-
cant, and conclusions of the study were limited by the small
sample of clinics. To our knowledge, no other studies have
explored the question of whether psychological outcomes
vary across cancer clinics.
Therefore, the aim of the present study was to examine in a
large sample of medical and haematology clinics: (a) whether
there is significant variation in patient anxiety and depression
across clinics independent of sociodemographic, disease and
treatment factors.
Methods
Setting and design A cross sectional survey was undertaken
involving patients recruited from medical oncology and
haematology clinics in Australia. Ethics approval, in accor-
dance with the Helskini Declaration of the World Medical
Association, was obtained from the Cancer Institute of New
South Wales (2011/10/351) and the University of Newcastle
Human Research Ethics (H-2010-1324) Committees, as well
from ethics committees associated with each participating site.
Recruitment of clinicsMedical oncology clinics were eligible
if they treated at least 400 new patients each year. A leading
medical oncologist from each state acted as a ‘clinical cham-
pion’ to help with recruitment for the study. These individuals
identified clinics which met the inclusion criteria, and sent a
written invitation. Additional information was provided by
phone, email and/or in-person by the research team.
Patient sample Patients with a confirmed diagnosis of cancer,
aged 18 years or older, English speaking and presenting for an
outpatient haematology or medical oncology consultation
were eligible to participate. Those unable to complete the sur-
vey independently were excluded. As it would be unreason-
able to attribute psychological outcomes to clinic characteris-
tics for patients attending the clinic for the first time, these
patients were also excluded.
Recruitment of patients Consecutive patients were recruited
in each of the participating clinics. Eligible patients were in-
vited to participate and written informed consent was obtain-
ed. The age and sex of non-consenters were collected to assess
potential consent bias; no other information was collected due
to privacy restrictions. Participants were asked to complete a
pen and paper survey either in clinic or at home. Those who
took the survey home were asked to return it within 1 week.
Non-responders were mailed a second copy of the survey and
a reminder letter at 2–3 weeks. A second reminder letter was
sent 2–3 weeks after the first reminder.
Measures
Explanatory variables
Demographic variables: Age, sex, highest level of education,
Aboriginal and/ or Torres Strait Islander status, marital status,
country of birth, home postal code, living situation, employ-
ment, private health insurance, concession card status, and
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smoking status were obtained by patient self-report.
Concession cards are government issued cards that enable
the bearer to obtain discounts on health services and medi-
cines (e.g. for people on low incomes).
Disease and treatment variables included self-reported
cancer type, perceived stage of disease at diagnosis (ear-
ly or advanced), remission status, time since diagnosis,
cancer treatments, relocation for treatment and main rea-
son for hospital visit on the day of recruitment.
Outcome variable
The Hospital Anxiety and Depression Scale (HADS) was
used to assess psychological morbidity. The scale includes
an anxiety subscale (7 items), and a depression subscale (7
items) [14]. Each item is scored from 0 to 3, giving a maxi-
mum score of 21 for each subscale. The HADs has been wide-
ly used with cancer patients [15], and meets psychometric
criteria for internal consistency, construct validity, and dis-
criminant validity [15]. A score of 8 or above on the depres-
sion or anxiety subscales was used to indicate possible
caseness for depression or anxiety, respectively [15].
Statistical analysis
Between-clinic variation in anxiety or depression scores (as
determined by the HADS) was initially examined through
boxplots, and then formally assessed through random effect
linear regression models with anxiety or depression score as
the outcome and a random intercept for clinic effect. Model-
based estimates of the site level means (i.e. partially pooled
estimates) with 95% confidence intervals were displayed as
caterpillar plots for comparison. The statistical significance of
the clinic random effect variance was assessed by comparing
the model with a random effect to the equivalent linear model
without the random effect, the corresponding likelihood ratio
test (LRT) is assumed to follow a 50:50 mixture of chi-square
distributions. The intra-class correlation (ICC) was reported,
and where clinic variation in anxiety or depression was found
to be statistically significant (p < 0.05), we reported the corre-
sponding 95% confidence interval for the ICC obtained from
bootstrapping. We also determined if this variation could be
explained through differing patient level characteristics by
including the following patient demographic (age, sex, marital
status, highest level of education, smoking status, concession
card status, private health insurance status, Aboriginal and /or
Torres Strait Islander status and country of birth) and disease
and treatment characteristics (cancer type, time since diagno-
sis, stage at diagnosis and treatments received) as fixed effects
in the mixed-effects regression model and assessed the signif-
icance of the between-clinic variation using the method de-
scribed above. Classification of categorical variables was as
shown in Table 1. We also present results for estimates of the
ICC on the probability scale for depression and anxiety
dichotomised at a cut point of 8 or more. Logistic regression
within a generalised estimating equation framework assuming
a compound symmetric residual correlation matrix was used
for these analyses.
Sample size
A sample of approximately 2800 patients from 22 clinics (an
average of 127 participants per clinic) would enable a detec-
tion of differences in depression or anxiety scores between
any two sites of at least 0.35 standard deviation with 80%
power and a 5% significance level.
Results
Twenty-two clinics from 19 hospitals participated in the study.
Three hospitals had both a medical oncology and a
haematology clinic participate. One clinic was located in a
private hospital in a regional area, two clinics were located
in regional public hospitals, and the remaining 20 clinics were
located in public metropolitan hospitals. Most clinics (n = 21)
were located in teaching hospitals. Two clinics were located in
hospitals with less than 200 beds, 8 in hospitals with 200–500
beds and 12 in hospitals with more than 500 beds.
Of the 6036 patients screened, 4233 (70%) were consid-
ered eligible. Of these, 3472 agreed to participate (82%); 2811
returned a completed survey (81% of consenters) and were
included in the analysis. There were no statistically significant
differences in terms of the gender of consenters and non-
consenters (consenters 57% female, non-consenters 52% fe-
male, p = 0.056). Themedian number of participants per clinic
was 150 (minimum 17, maximum 195). Sociodemographic
characteristics of participants are presented in Table 1. Most
participants (n = 2561, 94%) reported that they had received
most of their cancer care from the hospital from which they
were recruited.
Depression scores across treatment clinics
Mean depression scores ranged from 3.7 to 5.4, with an over-
all mean of 4.57 (SD = 3.78). No evidence was found for
variation in HADS depression scores among clinics (random
effect variance LRT p value = 0.1232), (see Fig. 1), therefore
no further analysis for the depression outcome was undertak-
en. The overall proportion of those reporting elevated depres-
sion scores (≥ 8) was 21%, (n = 588) with rates varying from
12 to 32% across clinics and an intra-class correlation (ICC) of
0.0001.
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Anxiety scores across treatment clinics
The overall mean anxiety score was 5.24 (SD = 4.07) with
mean scores ranging from 3.9 to 6.4. There was evidence for
variation in HADS anxiety scores between clinics (random
effect variance LRT p value = 0.0002), with the ICC estimated
to be 0.011 (95% CI 0.005, 0.024) (see Fig. 2). The overall
proportion of those reporting elevated anxiety scores (≥ 8) was
Table 1 Demographic, disease and treatment characteristics of sample
Variable Category Oncology (n = 2096) n (%) Haematology (n = 715) n (%)
Gender Male 808 (39%) 408 (57%)
Age Less than 65 1187 (58%) 416 (59%)
Aboriginal and Torres Strait Islander origin Yes 29 (1.4%) 7(1.0%)
Marital status Married or partnered 1355 (66%) 469 (66%)
Single, divorced, separated or widowed 711 (34%) 239 (34%)
Highest level of education High school or below 1030 (50%) 321 (46%)
Vocational training, university or other 1026 (50%) 384 (54%)
Birth place Australia 1441 (70%) 495 (70%)
Other 627 (30%) 214 (30%)
Health insured Yes 861 (42%) 374 (52%)
Concession card Yes 1190 (58%) 399 (56%)
Smoking status Current smoker 206 (10%) 59 (8.3%)
Former smoker 882 (43%) 265 (37%)
Never smoked 975 (47%) 389 (55%)
Location of residence City 1229 (59%) 665 (94%)
Regional or remote 844 (41%) 39 (5.5%)
Living arrangements With others 1647 (80%) 564 (80%)
Employment Paid employment 641 (31%) 244 (34%)
Retired 847 (41%) 266 (37%)
No paid employment (home duties,
unemployed or disability pension)
570 (28%) 200 (28%)




Other cancer or more than 1 564 (28%) 357 (50%)
Myeloma 26 (1.3%) 148 (21%)
Non-Hodgkin lymphoma 46 (2.3%) 203 (29%)
Prostate 117 (5.7%)
Time since diagnosis 12 months or less 992 (48%) 203 (29%)
13 to 24 months 354 (17%) 121 (17%)
Over 24 months 723 (35%) 383 (54%)
Treatments ever received Surgery 1475 (71%) 146 (21%)
Chemotherapy 1684 (82%) 575 (82%)
Radiotherapy 1003 (51%) 163 (23%)
Hormone therapy 489 (25%) 16 (2.2%)
Biological therapy 250 (13%) 49 (6.9%)
Bone marrow transplant 6 (0.3%) 100 (14%)
Stem cell 17 (0.9%) 153 (21%)
Other* 30 (1.5%) 55 (7.7%)
Cancer stage Early 1113 (62%) 208 (30%)
Advanced 507 (28%) 166 (24%)
Do not know or in remission, or not applicable 163 (9.1%) 322 (46%)
*Numbers reported for each variable may not add to total sample size due to missing data
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27%, with rates varying from 12 to 38% across clinics and an
ICC of 0.0067.
The variation between treatment clinics in HADS anxiety
scores was not statistically significantly different than zero
once all demographic, disease and treatment predictors were
adjusted for (icc < 1%, between-site variation LRT p =
0.1351).
Discussion
The results from this study indicate that approximately one
fifth of medical oncology patients reported elevated levels of
depression and a quarter indicated clinical levels of anxiety
using standardised instruments. These rates are consistent
with other studies in the field [1, 2] suggesting the external
validity of the findings.
No variation in levels of clinical anxiety or depression
across cancer treatment clinics
To our knowledge, this is the first large scale study to examine
whether treatment clinics potentially contribute to variation in
psychological outcomes for cancer patients. Previous studies
suggest that clinic characteristics are associated with unwar-
ranted variation in important outcomes such as pain [12] and
Fig. 1 Caterpillar plot of the
mean depression scores across
haematology and medical
oncology clinics (estimated from
a random effects model). Model-
based means are a weighted
average of site-specific sample
mean and the grand mean.
Estimates from sites with large
variability and/or small sample
size are pooled toward to the
grand mean
Fig. 2 Caterpillar plot of the
mean anxiety scores across
haematology and medical
oncology clinics (estimated from
a random effects model). Model-
based means are a weighted
average of site-specific sample
mean and the grand mean.
Estimates from sites with large
variability and/or small sample
size are pooled toward the grand
mean
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mortality rates following surgery [4]. Jacobsen’s study [16]
found that indicators of psychosocial care varied across 11
medical oncology clinics; therefore, it is reasonable to expect
variation in psychological outcomes may also occur.
Therefore, our finding that, once patient factors were con-
trolled for, there was no significant variation across clinics
for depression or anxiety is surprising.
A number of hypotheses may explain why between-clinic
variation in psychological outcomes was not identified in the
present study.
There is a high degree of within-clinic variability
in psychosocial care
In Australia, while clinical practice guidelines were developed
for psychosocial care of adults with cancer in 2003 [17], these
have subsequently been rescinded. There is no requirement for
specific distress screening processes, or provision of specific
interventions, in order to gain accreditation. In the absence of
policy levers to ensure implementation of specific care pro-
cesses, individual clinicians have a high level of discretion
regarding the processes (or lack thereof) which they put in
place to detect and treat anxiety, depression and related out-
comes. Therefore, our results may reflect that within clinic
variability in the process of care used by clinicians within a
clinic was greater than between clinic variation in processes.
There is a high degree of similarity in the psychosocial
care provided across clinics
It is also possible that there is little within-clinic variation, and
that clinics implement very similar care processes. This would
also account for our finding of no variation in outcomes.
While private hospitals represent approximately 47% of all
hospitals in Australia [18], only one private hospital was in-
cluded in our sample due to prohibitive costs associated with
obtaining research ethics and governance approvals. A greater
representation of private clinics may have introduced greater
variability as it is the nature of private enterprise to strive to
differentiate oneself from the crowd by applying innovations
in products and processes.
Efficacious psychosocial care strategies
are not effective in real world settings, hence
variability (or lack of) in delivery across clinics does
not impact on outcomes
While numerous studies have demonstrated the efficacy of
specific treatments to improve the psychological well-being
of cancer patients [19–22], effectiveness studies are more lim-
ited. Efficacy studies are undertaken in optimal circumstances
with a focus on internal validity [23]. Often, this is achieved
by controlling for context in a way that does not reflect the real
world. Patient eligibility criteria, for example, are carefully
delineated (often excluding individuals with commonly
occurring co-morbidities, culturally diverse backgrounds and
limiting age range) [23]. Furthermore, clinicians involved in
intervention trials may be biased toward those who are already
committed to improving psychological care. Additionally, in
well-controlled research, the fidelity of adherence to the treat-
ment protocol is usually carefully monitored and maintained
[23]. These experimental conditions may not be achieved in
everyday clinical practice, diluting the potential effectiveness
of an intervention and limiting the generalisability of results.
Therefore, if efficacious interventions are implemented poor-
ly, or are ineffective in real-world settings, then variability in
care processes may not translate into variability in psycholog-
ical outcomes of patients. There is a need for the field to
undertake effectiveness studies (sometimes referred to as
pragmatic trials) where the power of the intervention is exam-
ined in real-world circumstances. In such studies, the evalua-
tion design is able to take proper account of context by
allowing a more realistic eligibility criteria, ensuring a range
of clinicians are involved, and allowing for the expected var-
iation in treatment fidelity.
Measurement error may have hindered the ability
to identify variability across clinics
The Hospital Anxiety and Depression Scale is a com-
monly used measure of psychosocial well-being. It has
acceptable psychometric properties, and scores are not
confounded by the physical symptoms of cancer or its
treatment [15]. However, it remains a screening tool,
and unlike a structured clinical interview, is not diag-
nostic. Therefore, it is possible that measurement error
may have impacted on the accuracy of the anxiety and
depression scores. In an effort to overcome uncertainty
about the optimal clinical cut-point for cancer popula-
tions [13], analysis for this paper was undertaken using
the HADS score as a continuous variable. Examining
the HADS score in this manner increases the statistical
power of the analysis.
Limitations
As discussed above, our results must be interpreted in light of
several limitations which may have affected the results. These
include potential measurement error, and a hospital sample
which consisted almost entirely of large metropolitan public
hospitals. Further, our study did not allow us to rule out pos-
sible explanations for the lack of variability observed such as
there being a high degree of within clinic variability in the
delivery of care.
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Conclusions
This study provides the first large scale examination of wheth-
er variability in psychological outcomes occurs across oncol-
ogy clinics. Our results indicate that there is no variation in
anxiety and depression outcomes across medical oncology
and haematology clinics.
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